Johnson & Johnson (JNJ)
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General